Biotech ETFs Climb on Biogen’s Promising Clinical Trial

This article was originally published on ETFTrends.com.

Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) increased 3.2%, First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT) advanced 2.9% and VanEck Vectors Biotech ETF (NYSEArca: BBH) was 2.8% higher. [...]

Continue Reading Below

Read more at ETFTrends.com >